KRAS G12C inhibitors in NSCLC forecast to achieve over $1bn in sales by 2024
GlobalData estimates that Amgen’s Lumakras (sotorasib) is set to become a blockbuster agent in non-small cell lung cancer.
By
Comment
Latest in
Comment
Macro view: Omicron to affect GDP growth if restrictions ease
Some economists believe that as holiday demand and supply chain woes ease, the situation should improve in 2022 but Omicron…
FDA approves Janus kinase inhibitors Rinvoq and Cibinqo despite safety concerns
The introduction of Rinvoq and Cibinqo to the atopic dermatitis market will provide more treatment options for many patients.
By
Macro View: Hanke hits out at Biden’s inflation explanation
White House officials are not buying the argument that inflation has risen mostly because of Biden’s $1.9tn American Rescue Plan,…
Virtual Care and Telemedicine: Technology trends
Listed below are the key technology trends impacting the virtual care and telemedicine theme, as identified by GlobalData. The integration…
By
Macro view: US seeks global process to update Covid-19 vaccines
Some economists expect that the US FDA will participate in a coordinated, global effort to update Covid-19 vaccines to tackle…
Covid-19 news: Omicron won’t be the last variant – WHO
Global: The global Covid death toll has passed the grim milestone of 5.5 million, with a figure of 5,554,983 according…
Macro view: Economic growth poised to slow in major economies
The OECD believes that the strong rebound after the Covid-19 economic crisis in 2020 may soon moderate in several major…